The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS.

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer / Puglisi F.; Gerratana L.; Lambertini M.; Ceppi M.; Boni L.; Montemurro F.; Russo S.; Bighin C.; De Laurentiis M.; Giuliano M.; Bisagni G.; Durando A.; Turletti A.; Garrone O.; Ardizzoni A.; Gamucci T.; Colantuoni G.; Gravina A.; De Placido S.; Cognetti F.; Del Mastro L.. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - ELETTRONICO. - 7:1(2021), pp. 82.1-82.9. [10.1038/s41523-021-00286-w]

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Ardizzoni A.;
2021

Abstract

The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS.
2021
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer / Puglisi F.; Gerratana L.; Lambertini M.; Ceppi M.; Boni L.; Montemurro F.; Russo S.; Bighin C.; De Laurentiis M.; Giuliano M.; Bisagni G.; Durando A.; Turletti A.; Garrone O.; Ardizzoni A.; Gamucci T.; Colantuoni G.; Gravina A.; De Placido S.; Cognetti F.; Del Mastro L.. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - ELETTRONICO. - 7:1(2021), pp. 82.1-82.9. [10.1038/s41523-021-00286-w]
Puglisi F.; Gerratana L.; Lambertini M.; Ceppi M.; Boni L.; Montemurro F.; Russo S.; Bighin C.; De Laurentiis M.; Giuliano M.; Bisagni G.; Durando A.; Turletti A.; Garrone O.; Ardizzoni A.; Gamucci T.; Colantuoni G.; Gravina A.; De Placido S.; Cognetti F.; Del Mastro L.
File in questo prodotto:
File Dimensione Formato  
s41523-021-00286-w.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 876.68 kB
Formato Adobe PDF
876.68 kB Adobe PDF Visualizza/Apri
Supplementary materials.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per accesso libero gratuito
Dimensione 73.2 kB
Formato Zip File
73.2 kB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/851521
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact